Clementia is innovating new treatments for rare bone disorders and other diseases.

Our name represents everything we do. Clementia is derived from the Latin term for compassion, a concept that inspires us every day.

Our mission is to bring innovative and effective treatment options to people who currently have none.

 

We are developing palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of individuals who are affected by fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases.

We are currently evaluating palovarotene in the MOVE trial, a confirmatory Phase 3 registrational clinical study, for the treatment of patients with FOP and in the MO-Ped trial – the first ever clinical trial assessing a potential therapeutic option for patients affected by MO. These devastating bone disorders are caused by genetic mutations that result in excessive cellular signaling in the bone morphogenetic protein (BMP) pathway –  signaling that palovarotene disrupts.

We believe that RARγ selective agonists have potential beyond rare bone disorders. We are also developing a palovarotene eye drop formulation for the treatment of dry eye disease, a condition that when advanced, can lead to pain, ulcers, or scars on the cornea, and loss of vision.

Leadership Team

Board of Directors